Page 2 of 8
General information about the clinical study
When and where was this study done?
The study started in September 2017 and ended in August 2021. All the study sites were in
the United States.
Which medicines were studied?
The medicines studied were:
 Niraparib
 Pembrolizumab
 Dostarlimab
The participants took niraparib alone or in combination with either pembrolizumab or
dostarlimab.
What was the main reason for this study?
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Common
symptoms include continuous cough, chest pain, weight loss, and tiredness. Advanced
NSCLC usually means that the cancer has spread beyond the lungs into other areas in the
body. A tumor is a solid mass of tissue that forms due to abnormal cell growth.
Immune cells have a type of protein on
their surface called programmed cell
death 1 (PD-1). Cancer medicines
attach to this protein and may help the
immune system attack and destroy the
cancer cells. Some lung cancer cells
have a type of protein on their surface